Encysive To Enter Dispute Resolution With FDA Over Third Thelin “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Company asserts that FDA’s data analysis of STRIDE-2 trial for Thelin does not follow special protocol assessment agreement.